<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11847935
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     02
    </month>
    <day>
     18
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     08
    </month>
    <day>
     12
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1060-0280
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       36
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Feb
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Annals of pharmacotherapy
     </title>
     <isoabbreviation>
      Ann Pharmacother
     </isoabbreviation>
    </journal>
    <articletitle>
     Effect of tablet splitting on serum cholesterol concentrations.
    </articletitle>
    <pagination>
     <medlinepgn>
      205-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To evaluate the effects of tablet splitting on low-density lipoprotein (LDL) cholesterol and total cholesterol values in patients taking simvastatin and atorvastatin.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      A retrospective chart review of total cholesterol and LDL cholesterol values of patients instructed to split simvastatin or atorvastatin between January 1999 and November 2000.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Veterans Affairs Medical Center in Huntington, WV.
     </abstracttext>
     <abstracttext label="PATIENTS" nlmcategory="METHODS">
      Patients were included if they were taking simvastatin or atorvastatin with regular lipid management and follow-up laboratory results. Patients were required to remain on the same milligram-per-day dose at least 6-8 weeks before and after tablet-splitting initiation and have cholesterol values drawn at least 6 weeks after initiation of both whole-tablet and half-tablet dosing. Patients were excluded if they had a triglyceride level &gt; 400 mg/dL or were noncompliant on the basis of pharmacy records and provider notes. MEASUREMENT OUTCOMES: The primary end points were changes in total cholesterol and LDL cholesterol values before and after the patient was switched to half-tablet therapy.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The overall results for this review demonstrated no statistically significant increase in total cholesterol and LDL cholesterol concentrations. Total cholesterol and LDL cholesterol values actually decreased from presplitting to postsplitting, p = 0.017 and p = 0.003, respectively.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The investigation showed that half-tablet dosing was as effective as whole-tablet dosing. The program will be continued as a part of quality patient care at the Huntington Veterans Affairs Medical Center.
     </abstracttext>
    </abstract>
    <affiliation>
     Veterans Affairs Medical Center, Huntington, WV, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Duncan
      </lastname>
      <forename>
       Megan C
      </forename>
      <initials>
       MC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Castle
      </lastname>
      <forename>
       Sharon S
      </forename>
      <initials>
       SS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Streetman
      </lastname>
      <forename>
       Daniel S
      </forename>
      <initials>
       DS
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Ann Pharmacother
    </medlineta>
    <nlmuniqueid>
     9203131
    </nlmuniqueid>
    <issnlinking>
     1060-0280
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Cholesterol, LDL
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Heptanoic Acids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Pyrroles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Tablets
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      110862-48-1
     </registrynumber>
     <nameofsubstance>
      atorvastatin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      57-88-5
     </registrynumber>
     <nameofsubstance>
      Cholesterol
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      79902-63-9
     </registrynumber>
     <nameofsubstance>
      Simvastatin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cholesterol
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cholesterol, LDL
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cross-Over Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Costs
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heptanoic Acids
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      economics
     </qualifiername>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pyrroles
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      economics
     </qualifiername>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Retrospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Simvastatin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      economics
     </qualifiername>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tablets
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      West Virginia
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      2
     </month>
     <day>
      19
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      8
     </month>
     <day>
      13
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      2
     </month>
     <day>
      19
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11847935
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

